Imatinib quantification in human serum with LC-MS3 as an effective way of protein kinase inhibitor analysis in biological matrices
-
Marek Dziadosz
,
Michael Klintschar
Abstract
Background:
As imatinib gained a lot of attention in the field of medicine, appropriate methods are needed for drug analysis. LC-MS/MS combined with complex sample preparation and column enrichment is usually the method of choice when high sensitivity is necessary. The application of LC-MS3 in imatinib quantification has not been discussed in the literature.
Methods:
An LC-MS3 imatinib quantification method was developed and validated in human serum. The sample preparation was based on the liquid-liquid extraction of 50 μL human serum. Chromatographic separation was performed using a Luna 5 μm C18 (2) 100 A, 150 mm×2 mm column and the elution was done using a mobile phase consisting of A (H2O/methanol=95/5, v/v) and B (H2O/methanol=3/97, v/v), both with 10 mM ammonium acetate and 0.1% acetic acid.
Results:
The conditions applied resulted in a limit of detection/quantification value of 0.14/0.45 ng/mL reached without a sophisticated sample preparation technique or enrichment column application. It could be demonstrated that MS3 detection is a very effective way of sensitive imatinib quantification. Further, it could be stated that the strategy presented can be very useful for a sensitive analysis of other protein kinase inhibitors, because their molecule structure is appropriate for MS3 detection.
Conclusions:
The presented analytical strategy is an effective way of protein kinase inhibitor analysis in human serum.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Baselt RC. Disposition of toxic drugs and chemicals in men, 9th ed. Seal Beach: Biomedical Publications, 2011.Search in Google Scholar
2. Birch M, Morgan PE, Handley S, Ho A, Ireland R, Flanagan RJ. Sample methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib. Biomed Chromatogr 2013;27:335–42.10.1002/bmc.2796Search in Google Scholar PubMed
3. Caterino M, Casadei GM, Arvonio R, De Francia S, Pirro E, Piccione FM, et al. Quantification of imatinib plasma levels in patients with chronic myeloid leukemia: comparison between HPLC-UV and LC-MS/MS. Int Pept Res Ther 2013;19:109–16.10.1007/s10989-012-9321-0Search in Google Scholar
4. Miura M, Takahashi N, Sawada K. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection. J Chromatogr Sci 2011;49:412–5.10.1093/chromsci/49.5.412Search in Google Scholar PubMed
5. Dziadosz M, Bartels H. Imatinib quantification in human serum for clinical purposes using high performance liquid chromatography with diode array detector. Acta Chim Slov 2011;58:347–50.Search in Google Scholar PubMed
6. Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L, Gupta SK. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J Chromatogr B 2004;804:431–4.10.1016/j.jchromb.2004.01.032Search in Google Scholar PubMed
7. Widmer N, Béguin A, Rochat B, Buclin T, Kovacsovics T, Duchosal MA, et al. Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B 2004;803:285–92.10.1016/j.jchromb.2004.01.006Search in Google Scholar PubMed
8. Guetens G, Prenen H, De Boeck G, van Oosterom A, Schöffski P, Highley M, et al. Simultaneous determination of AMN107 and imatinib (Gleevec®, Glivec®, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection. J Chromatogr B 2007;846:341–5.10.1016/j.jchromb.2006.08.004Search in Google Scholar PubMed
9. Schleyer E, Pursche S, Köhne CH, Schuler U, Renner U, Gschaidmeier H, et al. Liquid chromatographic method for detection and quantification of STI–571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. J Chromatogr B 2004;799:23–36.10.1016/j.jchromb.2003.10.025Search in Google Scholar PubMed
10. Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N, et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta 2011;412:1060–7.10.1016/j.cca.2011.02.023Search in Google Scholar PubMed
11. Götze L, Hegele A, Metzelder SK, Renz H, Nockher WA. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clin Chim Acta 2012;413:143–9.10.1016/j.cca.2011.09.012Search in Google Scholar PubMed
12. Zhang Y, Qiang S, Yu Z, Zhang W, Xu Z, Yang L, et al. LC-MS/MS determination of imatinib and N-desmethyl imatinib in human plasma. J Chromatogr Sci 2014;52:344–50.10.1093/chromsci/bmt037Search in Google Scholar PubMed
13. Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF, Ruiz-Nuno A. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human serum. Biomed Chromatogr 2013;27:502–8.10.1002/bmc.2819Search in Google Scholar
14. Klawitter J, Zhang YL, Klawitter J, Anderson N, Serkova NJ, Christians U. Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture. Biomed Chromatogr 2009;23:1251–8.10.1002/bmc.1247Search in Google Scholar PubMed
15. Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B 2002;768:325–40.10.1016/S1570-0232(01)00611-0Search in Google Scholar
16. Andriamanana I, Gana I, Duretz B, Hulin A. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B 2013;926: 83–91.10.1016/j.jchromb.2013.01.037Search in Google Scholar PubMed
17. Dziadosz M, Lessig R, Bartels H. HPLC-DAD protein kinase inhibitor analysis in human serum. J Chromatogr B 2012; 893–894:77–81.10.1016/j.jchromb.2012.02.037Search in Google Scholar PubMed
18. Dziadosz M, Lessig R, Bartels H. Protein kinase inhibitor analysis with the core-shell separation technique. Anal Bioanal Chem 2012;404:2083–6.10.1007/s00216-012-6316-9Search in Google Scholar PubMed
19. Dziadosz M, Wagner MC, Lipka DB, Fischer T, Bartels H. High-performance liquid chromatography with ultraviolet detection and protein precipitation as a way of quantitative determination of nilotinib with and without internal standard. J Liq Chrom Rel Technol 2012;35:2503–10.10.1080/10826076.2011.636469Search in Google Scholar
20. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75:3019–30.10.1021/ac020361sSearch in Google Scholar PubMed
©2017 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Original Articles
- Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration
- Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats
- Imatinib quantification in human serum with LC-MS3 as an effective way of protein kinase inhibitor analysis in biological matrices
- Preliminary study of the association between the elimination parameters of phenytoin and phenobarbital
- Effects of the genetic variants of organic cation transporters 1 and 3 on the pharmacokinetics of metformin in Jordanians
- Short Communications
- Carboxylesterase 1A2 encoding gene with increased transcription and potential rapid drug metabolism in Asian populations
- Need for pharmacogenetic studies on the prevalence of MTHFR mutations in Puerto Ricans and Hispanics
Articles in the same Issue
- Frontmatter
- Original Articles
- Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration
- Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats
- Imatinib quantification in human serum with LC-MS3 as an effective way of protein kinase inhibitor analysis in biological matrices
- Preliminary study of the association between the elimination parameters of phenytoin and phenobarbital
- Effects of the genetic variants of organic cation transporters 1 and 3 on the pharmacokinetics of metformin in Jordanians
- Short Communications
- Carboxylesterase 1A2 encoding gene with increased transcription and potential rapid drug metabolism in Asian populations
- Need for pharmacogenetic studies on the prevalence of MTHFR mutations in Puerto Ricans and Hispanics
